These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16087947)

  • 1. Ovarian suppression for breast cancer: an effective treatment in search of a home.
    Krop IE; Winer EP
    J Clin Oncol; 2005 Sep; 23(25):5869-72. PubMed ID: 16087947
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 5. Ovarian cysts in tamoxifen-treated women with breast cancer.
    Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 7. Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer.
    Altundag K; Altundag O; Gunduz M
    Breast Cancer Res Treat; 2005 Jan; 89(2):213. PubMed ID: 15692765
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
    Ruddy KJ; Partridge AJ
    Oncology (Williston Park); 2009 Jan; 23(1):34, 40. PubMed ID: 19283919
    [No Abstract]   [Full Text] [Related]  

  • 13. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
    Wolff AC; Davidson NE
    J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT; Andersen J
    Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.
    McDonald Wade S; Hackney MH; Khatcheressian J; Lyckholm LJ
    Oncology; 2008; 75(3-4):192-202. PubMed ID: 18841034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Brown RJ; Davidson NE
    Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.